Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

The Prostate

Showing results (501-510 of 6,084) with videos related to

Pageof 609
Sort By:
The Prostate|January 1, 1992
The prognostic value of histological grading and mean nuclear volume in human prostatic cancerK Nielsen, G H Berild, E Bruun, et al.
The Prostate|January 21, 2006
Tumor-related immunity in prostate cancer patients treated with human recombinant granulocyte monocyte-colony stimulating factor (GM-CSF)Thomas Schwaab, Christopher P G Tretter, Jennifer J Gibson, et al.
The Prostate|March 1, 1996
Expression of CD44 isoforms in human prostate tumor cell linesJ W Stevens, P L Palechek, T L Griebling, et al.
The Prostate|March 1, 1996
Low incidence of androgen receptor gene mutations in human prostatic tumors using single strand conformation polymorphism analysisB A Evans, M E Harper, C E Daniells, et al.
The Prostate|March 1, 1996
Inhibitory effects of the nucleoside analogue gemcitabine on prostatic carcinoma cellsM V Cronauer, H Klocker, H Talasz, et al.
The Prostate|March 1, 1996
Control of LNCaP proliferation and differentiation: actions and interactions of androgens, 1alpha,25-dihydroxycholecalciferol, all-trans retinoic acid, 9-cis retinoic acid, and phenylacetateM Esquenet, J V Swinnen, W Heyns, et al.
The Prostate|October 1, 1996
Estrogen reduction by aromatase inhibition for benign prostatic hyperplasia: results of a double-blind, placebo-controlled, randomized clinical trial using two doses of the aromatase-inhibitor atamestane. Atamestane Study GroupA Radlmaier, H U Eickenberg, M S Fletcher, et al.
The Prostate|October 1, 1996
Expression of transforming growth factor-beta 1 in rat ventral prostate and Dunning R3327 PAP prostate tumor after castration and estrogen treatmentP Lindström, A Bergh, I Holm, et al.
The Prostate|October 6, 1998
Effects of long-term treatment with Serenoa repens (Permixon) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasiaF Di Silverio, S Monti, A Sciarra, et al.
The Prostate|November 27, 1998
Double-blind, placebo-controlled trial to assess the efficacy and tolerability of mepartricin in the treatment of BPHL Denis, F Pagano, A Nonis, et al.
Pageof 609

Showing results (501-510 of 6,084) with videos related to

Sort By:
Pageof 609
The Prostate|January 1, 1992
The prognostic value of histological grading and mean nuclear volume in human prostatic cancerK Nielsen, G H Berild, E Bruun, et al.
The Prostate|January 21, 2006
Tumor-related immunity in prostate cancer patients treated with human recombinant granulocyte monocyte-colony stimulating factor (GM-CSF)Thomas Schwaab, Christopher P G Tretter, Jennifer J Gibson, et al.
The Prostate|March 1, 1996
Expression of CD44 isoforms in human prostate tumor cell linesJ W Stevens, P L Palechek, T L Griebling, et al.
The Prostate|March 1, 1996
Low incidence of androgen receptor gene mutations in human prostatic tumors using single strand conformation polymorphism analysisB A Evans, M E Harper, C E Daniells, et al.
The Prostate|March 1, 1996
Inhibitory effects of the nucleoside analogue gemcitabine on prostatic carcinoma cellsM V Cronauer, H Klocker, H Talasz, et al.
The Prostate|March 1, 1996
Control of LNCaP proliferation and differentiation: actions and interactions of androgens, 1alpha,25-dihydroxycholecalciferol, all-trans retinoic acid, 9-cis retinoic acid, and phenylacetateM Esquenet, J V Swinnen, W Heyns, et al.
The Prostate|October 1, 1996
Estrogen reduction by aromatase inhibition for benign prostatic hyperplasia: results of a double-blind, placebo-controlled, randomized clinical trial using two doses of the aromatase-inhibitor atamestane. Atamestane Study GroupA Radlmaier, H U Eickenberg, M S Fletcher, et al.
The Prostate|October 1, 1996
Expression of transforming growth factor-beta 1 in rat ventral prostate and Dunning R3327 PAP prostate tumor after castration and estrogen treatmentP Lindström, A Bergh, I Holm, et al.
The Prostate|October 6, 1998
Effects of long-term treatment with Serenoa repens (Permixon) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasiaF Di Silverio, S Monti, A Sciarra, et al.
The Prostate|November 27, 1998
Double-blind, placebo-controlled trial to assess the efficacy and tolerability of mepartricin in the treatment of BPHL Denis, F Pagano, A Nonis, et al.
Pageof 609